Stockscreener 앱 받기
43.35
1.70%
-0.885
Sanofi Adr 주식(SNY)의 최신 뉴스
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - AD HOC NEWS
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
European ADRs Drift Lower In US Trading - Finimize
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - Investing.com
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNY Stock Quote Price and Forecast - CNN
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Sanofi SA (HAM:SNW2) Stock Price, Trades & News - GuruFocus
NOK Stock Slides As ADR Weakness Puts Pressure On Bulls - StocksToTrade
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
NOK Stock Slips Again As ADR Weakness Worries Traders - StocksToTrade
Sanofi stock slides as price lingers below the long-term average - Traders Union
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sahm
9 New 5-Star Stocks This Week - Morningstar
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
662283 Forecast — Price Target — Prediction for 2027 - TradingView
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims - Sahm
Sanofi faces EU probe, shares steady after Friday’s Reuters report - ad-hoc-news.de
Sanofi SA Sponsored ADR Actuals & Estimates (NASDAQ:SNY) - TradingView
Enterprise value to revenue forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to earnings forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY) - Seeking Alpha
Price to book forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection - Sahm
Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers - AD HOC NEWS
1.25%
0.14%
자본화:
|
볼륨(24시간):